Randomized trial · people
Orforglipron 36 mg: 11.2% weight loss at 72 weeks in ATTAIN-1
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In a large 72-week trial, daily oral orforglipron led to more weight loss than placebo at every dose tested, with gut side effects as the most common problem.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 3127
- Published
- 2025
- Journal
- N Engl J Med
What they tested
The team tested whether once-daily orforglipron, taken by mouth, lowers body weight more than placebo in adults with obesity who do not have diabetes.
How the study was done
A phase 3, multinational, randomized, double-blind, placebo-controlled trial in 3127 adults with obesity and no diabetes, who took orforglipron at 6 mg, 12 mg or 36 mg, or placebo (a dummy treatment), once a day for 72 weeks. Everyone also followed a healthy diet and physical activity.

Model. Individual results vary.
What they found
At 72 weeks, average body weight changed by -7.5% in the 6 mg arm, -8.4% in the 12 mg arm and -11.2% in the 36 mg arm, compared with -2.1% on placebo, and each dose beat placebo. In the 36 mg arm, 54.6% lost at least 10% of their weight, 36.0% lost at least 15% and 18.4% lost at least 20%, compared with 12.9%, 5.9% and 2.8% on placebo. Waist size, systolic blood pressure (the top number), triglycerides and non-HDL cholesterol also improved more than on placebo. Side effects led 5.3 to 10.3% of people on orforglipron to stop treatment, versus 2.7% on placebo, and the most common were gut-related effects that were mostly mild to moderate.
What it doesn’t show
The trial included only adults with obesity who did not have diabetes, and it compared orforglipron with placebo, not with other weight-loss medicines. It was funded by Eli Lilly.
The paper
Wharton et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025.
The compound
More studies on Orforglipron
- Orforglipron: heart events no worse than insulin in ACHIEVE-4Randomized trial · people · 2026
- Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2Randomized trial · people · 2026
- Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3Randomized trial · people · 2026
- Orforglipron: food lowered drug exposure by 17.6% to 23.7%Clinical trial · people · 2024
- Every study on Orforglipron
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.